General information about company

Size: px

Start display at page:

Download "General information about company"

Godwin Ross
5 years ago
Views:

1 11/5/ BDL RESULTS SEPT REPORT.html General information about company Scrip code Name of company Result Type Class of security BERYL DRUGS LTD Main Format Equity Date of start of financial year Date of end of financial year Date of board meeting when results were approved Date on which prior intimation of the meeting for considering financial results was informed to the exchange Description of presentation currency Level of rounding used in financial results Reporting Quarter Nature of report standalone or consolidated Whether results are audited or unaudited Segment Reporting Description of single segment INR Thousands Half yearly Standalone Unaudited Single segment Pharmaceutical Indusrty file:///c:/users/acer/desktop/bdl%20results%20sept%20report.html 1/8

2 11/5/ BDL RESULTS SEPT REPORT.html A B C D Quarterly & Half Yearly Financial Result by Companies Other than Banks Date of start of reporting period Date of end of reporting period Part I Whether results are audited or unaudited Nature of report standalone or consolidated 1 Revenue From Operations 2 Expenses (a) (b) (c) (d) (e) (f) Net sales or Revenue from Operations Other operating revenues Total Revenue from operations (net) Cost of materials consumed Purchases of stock intrade Changes in inventories of finished goods, work in progress and stock in trade Employee benefit expense Depreciation and amortisation expense Other Expenses 3 months Previous accounting year ended (dd mmyyyy) Previous 3 months Corresponding 3 months ended in the previous year (ddmm yyyy) Year to date figures for current period Year to date figures for previous period Unaudited Unaudited Unaudited Unaudited Unaudited Audited Standalone Standalone Standalone Standalone Standalone Standalone others Total other expenses Total expenses file:///c:/users/acer/desktop/bdl%20results%20sept%20report.html 2/8

3 11/5/ BDL RESULTS SEPT REPORT.html A B C D 3 Date of start of reporting period Date of end of reporting period Whether results are audited or unaudited Nature of report standalone or consolidated Part I operations before other income, finance costs and exceptional Quarterly & Half Yearly Financial Result by Companies Other than Banks 3 months Previous accounting year ended (dd mmyyyy) Previous 3 months Corresponding 3 months ended in the previous year (dd mm yyyy) Year to date figures for current period Year to date figures for previous period Unaudited Unaudited Unaudited Unaudited Unaudited Audited Standalone Standalone Standalone Standalone Standalone Standalone Other income ordinary activates before finance costs and exceptional Finance costs ordinary activities after finance costs but before exceptional Prior period before tax Exceptional ordinary activities before tax Tax Expense Net profit (loss) from ordinary activities after tax Extraordinary Net Profit Loss for the period from continuing operations discontinuing operations before tax Tax expense of discontinuing operations Net profit (loss) from discontinuing operation after tax Profit (loss) for period before minority interest Net Profit (loss) after taxes minority interest and share of profit (loss) of associates file:///c:/users/acer/desktop/bdl%20results%20sept%20report.html 3/8

4 11/5/ BDL RESULTS SEPT REPORT.html A B C D Date of start of reporting period Date of end of reporting period Whether results are audited or unaudited Nature of report standalone or consolidated Part I Quarterly & Half Yearly Financial Result by Companies Other than Banks 3 months Year to date figures for previous period Details of equity share capital Paid up equity share capital Face value of equity share capital 23 Details of debt securities 24 Reserves excluding revaluation reserve 26 Earnings per share i ii 30 Earnings per share before Basic earnings per share before Diluted earnings per share before Previous 3 months Corresponding 3 months ended in the previous year (ddmm yyyy) Year to date figures for current period Previous accounting year ended (dd mm yyyy) Unaudited Unaudited Unaudited Unaudited Unaudited Audited Standalone Standalone Standalone Standalone Standalone Standalone Earnings per share after Basic earnings per share after Diluted earnings per share after Disclosure of notes on financial results Textual Information(1) file:///c:/users/acer/desktop/bdl%20results%20sept%20report.html 4/8

5 11/5/ BDL RESULTS SEPT REPORT.html Text Block 1. The Standalone results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meeting held on 5th Nov.. 2. In accordance with the requirements of Clause 41 of the Listing Agreement with the Stock Exchange, the Statutory Auditors have performed a limited review of the Companys financial results for the quarter ended Sep. 30, there are no qualifications. Textual Information(1) 3. The Income from Operations is from one segment namely Pharmaceutical Indusrty. 4. Previous period exp. have been regrouped / rearranged, wherever necessary. 5.taxes and depreciation are calculated on proportionate basis on annual estimated basis. 6. There were no Investors complaints pending at the beginning of the quarter and one complaint were received during the quarter ended Sep. 30,. file:///c:/users/acer/desktop/bdl%20results%20sept%20report.html 5/8

6 11/5/ BDL RESULTS SEPT REPORT.html Equity and liabilities 1 Shareholders' funds Statement of Asset and Liabilities Half year Previous year Date of start of reporting period Date of end of reporting period Whether results are audited or unaudited Unaudited Audited Nature of report standalone or consolidated Standalone Standalone Share capital Reserves and surplus Money received against share warrants Total shareholders' funds Share application money pending allotment Deferred government grants Non current liabilities Long term borrowings 0 35 Deferred tax liabilities (net) Foreign currency monetary item translation difference liability account Other long term liabilities Long term provisions Current liabilities Total non current liabilities Short term borrowings Trade payables Other current liabilities Short term provisions Assets 1 Non current assets (i) Fixed assets Total current liabilities Total equity and liabilities Tangible assets Producing properties Intangible assets Preproducing properties Tangible assets capital work in progress Intangible assets under development or work in progress Total fixed assets file:///c:/users/acer/desktop/bdl%20results%20sept%20report.html 6/8

7 11/5/ BDL RESULTS SEPT REPORT.html Statement of Asset and Liabilities Half year Previous year Date of start of reporting period Date of end of reporting period Whether results are audited or unaudited Unaudited Audited Nature of report standalone or consolidated Standalone Standalone (ii) Non current investments (v) Deferred tax assets (net) (vi) Foreign currency monetary item translation difference asset account (vii) Long term loans and advances (viii) Other non current assets Current assets Total non current assets Current investments 0 0 Inventories Trade receivables Cash and bank balances Short term loans and advances Other current assets Disclosure of notes on assets and liabilities Total current assets Total assets file:///c:/users/acer/desktop/bdl%20results%20sept%20report.html 7/8

8 11/5/ BDL RESULTS SEPT REPORT.html file:///c:/users/acer/desktop/bdl%20results%20sept%20report.html 8/8

General information about company

General information about company Scrip code 524606 Name of company BERYL Drugs Ltd Result Type Main Format Class of security Equity Date of start of financial year 01-04-2017 Date of end of financial